How to Outpace Your Competition: Interview with Contraline CEO Kevin Eisenfrats

In this episode of Medsider Radio, we had a fun conversation with Kevin Eisenfrats, CEO of Contraline. Kevin and his team are developing ADAM, a novel, long-lasting, reversible male contraceptive.

Kevin is a first-time entrepreneur and nanomedical engineer from the University of Virginia (UVA) and has been working on contraceptive technologies since his undergrad years. He has amassed over 50 patents in contraceptive drugs, medical devices, and biomaterials. In 2017, he was honored with a place among the Forbes 30 Under 30 in Healthcare.

In this interview, Kevin offers insights on how to move swiftly through clinical trials, community-building in medtech, creative fundraising efforts, and the importance of executing thorough scientific and market research.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Kevin Eisenfrats.